This trial is evaluating whether Lenalidomide will improve 2 primary outcomes and 8 secondary outcomes in patients with Follicular Lymphoma ( FL). Measurement will happen over the course of Timeframe: CR/CRu rate at 120 weeks.
This trial requires 1030 total participants across 2 different treatment groups
This trial involves 2 different treatments. Lenalidomide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Signs and symptoms of lymphoma typically indicate the disease, but there may be some overlap with other neoplastic disorders such as thyroid disease.\n\n- Breast Cancer Information Core – Clinical and Genetic Information\n- Breast Cancer Information Center – Signs and Symptoms of Breast Cancer"
"Horsfieldia longifurca\n\nHorsfieldia longifurca (also called long-haired horsfieldia, long-tailed horsfieldia or long-whiskered horsfieldia) is a species of plant in the family Myristicaceae." - Anonymous Online Contributor
"Around 1.6 million Americans are diagnosed with [follicular lymphoma](https://www.withpower.com/clinical-trials/follicular-lymphoma) a year, and 6.5 million Americans are diagnosed with non-Hodgkin's lymphoma, follicular, a year. These numbers represent the lowest estimates of lymphoma morbidity and mortality since 1950." - Anonymous Online Contributor
"Lymphoma and [follicular lymphoma](https://www.withpower.com/clinical-trials/follicular-lymphoma) treatment options and typical chemotherapy regimens are summarized. Lymphoma patients are typically treated with chemotherapy in order to achieve a long-term remission. Patients with follicular and some types of mantle cell disease generally receive either chemotherapy or watchful waiting. More research should focus on novel therapies for relapsed cancers like follicular lymphoma." - Anonymous Online Contributor
"Findings from a recent study showed that nodular peripheral lymphoma had the most aggressive clinical courses with patients experiencing early disease progression or relapse. Patients with less aggressive clinical courses were more likely to present with aggressive lymphomas with multiple sites." - Anonymous Online Contributor
"Lymphoma, follicular is caused by mutations in genes responsible for a number of signalling pathways. There is limited evidence for other possible causes with the probable exception of the Epstein-Barr virus, which is frequently present in patients with the condition." - Anonymous Online Contributor
"Although there is a high complication rate with therapy, patients with follicular lymphoma can expect and enjoy a better life. This is the second report of a cure for follicular lymphoma." - Anonymous Online Contributor
"LFS was shorter in patients who received bortezomib, a VEGF inhibitor, in combination with rituximab. LFS was not affected by the presence of other disease (extranodal disease or age>61 yr); however, there was a significant effect on LFS when patients received bortezomib on the basis of age (P=.068)." - Anonymous Online Contributor
"Lenalidomide has been reported to cause a number of side effects, including nausea, vomiting, fatigue, leukopenia, thrombocytopenia, and diarrhea. Other side effects less frequently include fever, pneumonia, cough, and diarrhea with constipation. Lenalidomide is contraindicated in recipients of organ transplants and pregnant women. If a patient has to interrupt treatment, this can be due to a serious, life-threatening condition. In rare cases, lenalidomide can cause neurological disturbances, including seizures, and severe liver damage as well. The frequency of these effects is not known." - Anonymous Online Contributor
"The family history of cancer has shown no influence on the occurrence of lymphomatous disease. This supports the hypothesis that other genetic factors, or other environmental factors, may play a role in the pathogenesis of lymphoma or lymphomania." - Anonymous Online Contributor
"Patients who meet these criteria should qualify for clinical trials investigating potential therapies for NHL and FTLD:\n1) Primary or relapsing disease (recurrence after treatment) in patients of all ages, with or without previous chemotherapy or radiotherapy exposure, whose disease has progressed and cannot be treated with any existing modalities such as glucocorticoids and methotrexate.\n2) Patients under 40 years of age who have progressive or relapsing disease or have a first-degree family history supporting a genetic predisposition for the disease.\n3) Patients with extranodal disease that progresses despite treatment." - Anonymous Online Contributor
"Lenalidomide is effective in a variety of B lineage cell malignancies, and its mechanisms of action appear to be associated with a shift in the immunophenotype of B-cells and with deregulation of multiple cell signaling pathways." - Anonymous Online Contributor
"The primary cause in the majority (75%) of cases is EBV-infection in the mantle zone of GCs. The primary cause in 25% of cases remains unclear. EBV-infection leads to increased expression of BCL-6 in B-cells and overexpression of p21 in B-cells as well as in T-cells, which leads to proliferation and multiplication of EBV-infected B-cells and/or T-cells, respectively. This leads to the differentiation of marginal zone B-cells into mantle zone B-cells, which are mostly EBV-negative. It follows that B-cells in the mantle zone of a GC are inactivated in most cases by EBV-infection." - Anonymous Online Contributor